JP2020528922A5 - - Google Patents

Info

Publication number
JP2020528922A5
JP2020528922A5 JP2020505412A JP2020505412A JP2020528922A5 JP 2020528922 A5 JP2020528922 A5 JP 2020528922A5 JP 2020505412 A JP2020505412 A JP 2020505412A JP 2020505412 A JP2020505412 A JP 2020505412A JP 2020528922 A5 JP2020528922 A5 JP 2020528922A5
Authority
JP
Japan
Prior art keywords
carbon atoms
groups
trisubstituted
disubstituted
unsubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020505412A
Other languages
English (en)
Japanese (ja)
Other versions
JP7336434B2 (ja
JP2020528922A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2018/067797 external-priority patent/WO2019025099A1/en
Publication of JP2020528922A publication Critical patent/JP2020528922A/ja
Publication of JP2020528922A5 publication Critical patent/JP2020528922A5/ja
Application granted granted Critical
Publication of JP7336434B2 publication Critical patent/JP7336434B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020505412A 2017-08-01 2018-07-02 アデノシン受容体アンタゴニストとしてのチアゾロピリジン誘導体 Active JP7336434B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17184272.7 2017-08-01
EP17184272 2017-08-01
PCT/EP2018/067797 WO2019025099A1 (en) 2017-08-01 2018-07-02 THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS

Publications (3)

Publication Number Publication Date
JP2020528922A JP2020528922A (ja) 2020-10-01
JP2020528922A5 true JP2020528922A5 (enExample) 2022-10-04
JP7336434B2 JP7336434B2 (ja) 2023-08-31

Family

ID=59506176

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020505412A Active JP7336434B2 (ja) 2017-08-01 2018-07-02 アデノシン受容体アンタゴニストとしてのチアゾロピリジン誘導体

Country Status (23)

Country Link
US (1) US11186592B2 (enExample)
EP (1) EP3661941B1 (enExample)
JP (1) JP7336434B2 (enExample)
KR (1) KR102717280B1 (enExample)
CN (1) CN110997681B (enExample)
AU (1) AU2018309265B2 (enExample)
CA (1) CA3071575A1 (enExample)
DK (1) DK3661941T3 (enExample)
ES (1) ES2940407T3 (enExample)
FI (1) FI3661941T3 (enExample)
HR (1) HRP20230251T1 (enExample)
HU (1) HUE061308T2 (enExample)
IL (1) IL272284B2 (enExample)
LT (1) LT3661941T (enExample)
NZ (1) NZ760516A (enExample)
PL (1) PL3661941T3 (enExample)
PT (1) PT3661941T (enExample)
RS (1) RS64035B1 (enExample)
SG (1) SG11202000823WA (enExample)
SI (1) SI3661941T1 (enExample)
TW (1) TWI850199B (enExample)
WO (1) WO2019025099A1 (enExample)
ZA (1) ZA202001295B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR117844A1 (es) 2019-01-22 2021-09-01 Merck Patent Gmbh Derivados de tiazolopiridina como antagonistas del receptor de adenosina
CN112174943A (zh) * 2019-07-03 2021-01-05 四川大学 一种吲哚-2-酮类化合物在制备防治口腔细菌产品中的用途
EP4351640A1 (en) 2021-06-07 2024-04-17 Ares Trading S.A. Combination treatment of cancer
CN119654328A (zh) 2022-08-02 2025-03-18 默克专利股份公司 (S)-7-氧杂-2-氮杂-螺[4.5]癸烷-2-甲酸[7-(3,6-二氢-2H-吡喃-4-基)-4-甲氧基-噻唑并[4,5-c]吡啶-2-基]-酰胺的新型结晶形式及其共晶形式

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4125828A (en) 1972-08-04 1978-11-14 Med-El Inc. Method and apparatus for automated classification and analysis of cells
US4207554A (en) 1972-08-04 1980-06-10 Med-El Inc. Method and apparatus for automated classification and analysis of cells
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
DE69720965T2 (de) 1996-02-13 2004-02-05 Astrazeneca Ab Chinazolinderivate und deren verwendung als vegf hemmer
NZ331191A (en) 1996-03-05 2000-03-27 Zeneca Ltd 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
AU1688599A (en) 1998-01-05 1999-07-26 Eisai Co. Ltd. Purine derivatives and adenosine a2 receptor antagonists serving as preventives/remedies for diabetes
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
US6841549B1 (en) 1999-07-02 2005-01-11 Eisai Co., Ltd. Condensed imidazole compounds and a therapeutic agent for diabetes mellitus
AU2001258628A1 (en) 2000-05-31 2001-12-11 Astrazeneca Ab Indole derivatives with vascular damaging activity
AU2001281817B2 (en) * 2000-06-21 2005-11-24 F. Hoffmann-La Roche Ag Benzothiazole derivatives
MXPA02012905A (es) 2000-07-07 2004-07-30 Angiogene Pharm Ltd Derivados de colquinol como agentes de dano vascular..
MXPA02012903A (es) 2000-07-07 2004-07-30 Angiogene Pharm Ltd Derivados de colquinol como inhibidores de angiogenesis.
WO2004089942A2 (en) 2001-10-02 2004-10-21 Acadia Pharmaceuticals Inc. Benzimidazolidinone derivatives as muscarinic agents
EP1465634B1 (en) 2001-12-12 2014-10-22 The Government of the United States of America, as represented by the Secretary Department of Health and Human Services Methods for using adenosine receptor inhibitors to enhance immune response and inflammation
US6713499B2 (en) * 2001-12-12 2004-03-30 Hoffman-La Roche Inc. 7-Amino-benzothiazole derivatives
US20080070932A1 (en) 2003-04-09 2008-03-20 Chi Vu Triazolo[ 1,5-A] Pyrimidines And Pyrazolo[ 1,5-A] Pyrimidines And Methods Of Making And Using The Same
US6872833B2 (en) * 2003-04-14 2005-03-29 Hoffmann-La Roche Inc. Adenosine receptor ligands
PT1636223E (pt) * 2003-05-19 2008-05-06 F Hoffmann-La Roche Ag Derivados de benzotiazole como ligandos de receptores da adenosina
RU2006112847A (ru) * 2003-09-19 2007-11-10 Ф. Хоффманн-Ля Рош Аг (Ch) Производные тиазолопиридина в качестве лигандов аденозинового рецептора
JP5202946B2 (ja) 2004-07-22 2013-06-05 エフ．ホフマン−ラ ロシュ アーゲー ベンゾチアゾール誘導体
ATE481409T1 (de) * 2006-05-18 2010-10-15 Hoffmann La Roche Thiazolopyramidin/pyridinharnstoffderivate als antagonisten am adenosin-a2b-rezeptor
US8168785B2 (en) * 2009-06-17 2012-05-01 Biotie Therapies, Inc. Benzothiazole derivatives
GB201416754D0 (en) * 2014-09-23 2014-11-05 Mission Therapeutics Ltd Novel compounds

Similar Documents

Publication Publication Date Title
JP2020531531A5 (enExample)
JP2020531526A5 (enExample)
JP2020528922A5 (enExample)
RU2506256C2 (ru) Лиганды для визуализации иннервации сердца
JP2019104748A5 (enExample)
JP2022524914A5 (enExample)
CA2324418A1 (en) Novel opiate compounds, methods of making and methods of use
EA200970171A1 (ru) Производные n-(аминогетероарил)-1н-индол-2-карбоксамидов, их получение и их применение в терапии
JP2023504542A5 (enExample)
JP2019077713A5 (enExample)
EA201070874A1 (ru) Производные индол-2-карбоксамидов и азаиндол-2-карбоксамидов, замещённых силанильной группой, их получение и применение в терапии
RU2009115653A (ru) Производные 5-замещенного хиназолинона, содержащие их композиции и способы их применения
DK191186A (da) Indolderivater
CA2457054A1 (en) Activator of peroxisome proliferator-activated receptor .delta.
EA201070871A1 (ru) Бициклические производные азабициклических карбоксамидов, их получение и их применение в терапии
JP2018516904A5 (enExample)
RU99128073A (ru) Замещенные 2-(2,6-диоксопиперидин-3-ил)-фталимиды и -1-оксоизоиндолины и способ снижения уровней фноа
RU2009125439A (ru) Комбинация ингибитора гда и антиметаболита
GB1046506A (en) Guanidine compounds and process for their manufacture
MX2024008480A (es) Compuesto heterociclico que contiene nitrogeno que tiene un efecto de activacion del factor 2 relacionado con el factor nuclear eritroide 2 (nrf2).
JP2021528421A5 (enExample)
RU2008146751A (ru) Новые производные имидазола, их получение и использование в качестве лекартвенных средств
RU2009102270A (ru) Производные тиазолилмочевины в качестве ингибиторов фосфатидилинозитол-3-киназы
KR920701178A (ko) 3-아릴옥사졸리디논 유도체, 그의 제조방법 및 그의 치료 용도
JP2025510945A5 (enExample)